CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2017 International Liver Cancer Association Annual Conference
Oncology Conference Multimedia
View more videos >>
Dr. Welling on CheckMate-040 Trial of Nivolumab in HCC
Dr. Montal on Molecular Predictors of Recurrence With Adjuvant Sorafenib in HCC
Dr. Finn on Significance of Phase III Findings of Lenvatinib in HCC
Oncology Conference Articles
Study Shows DAAs Are Not Associated With Increased HCC Recurrence Risk
Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).
BLU-554 Associated With Improved Response in HCC
BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.
Lenvatinib Continues to Show Noninferiority to Sorafenib in Liver Cancer
First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.
STORM Study Fails to Find Predictive Biomarkers for Sorafenib in HCC
Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.
Precision Screening May Improve Surveillance in HCC
Precision screening for hepatocellular carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach.
Mounting Excitement in HCC Examined at ILCA Meeting
Theodore H. Welling, MD, shares insight on the top presentations at the ILCA meeting, and how he believes the future will look for the treatment of HCC.
Finn Highlights Practice-Changing Studies in Liver Cancer
The 11th International Liver Cancer Association Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of hepatocellular carcinoma.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.